Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

Development of disease-modifying treatments for Alzheimer’s disease (AD) has been challenging, with no drugs approved to date. The failures of several amyloid-targeted programs have led many to dismiss the amyloid beta (Aβ) hypothesis of AD. An antiamyloid antibody aducanumab recently showed modest but significant efficacy in a phase 3 trial, Read & Research Alzheimer’s More

Leave a Reply